Last reviewed · How we verify
mRNA-1273.529
At a glance
| Generic name | mRNA-1273.529 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (PHASE2)
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (PHASE2, PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1273.529 CI brief — competitive landscape report
- mRNA-1273.529 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI